Immunophenotypic stability of Sézary cells by flow cytometry usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy

James Vaughan, Alexandra M. Harrington, Parameswaran N. Hari, Steven H. Kroft, Horatiu Olteanu

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Flow cytometry (FC) is frequently used to detect aberrant peripheral blood (PB) T cells ("Sézary cells") in patients with mycosis fungoides (MF) and Sézary syndrome (SS). However, immunophenotypic stability of MF/SS over time is not well characterized. We analyzed 141 PB samples from 9 cases (2 SS, 7 MF). At diagnosis, there were 3 to 5 immunophenotypic aberrancies per case (median, 4), including dim or absent CD2, CD3, CD4, CD5, CD7, or CD26 and bright CD45RO. Of 9 patients, 7 had a subsequent change in immunophenotype. All patients retained multiple aberrancies at follow-up (median, 3 per analysis; range, 2-6), of which 22.0% (81/369) were new. In 5 patients, a more than 99% decrease in absolute Sézary cell (ASC) counts by FC after alemtuzumab therapy or total skin electron beam radiation was associated with clinical improvement. We observed minor immunophenotypic changes over time in most patients with MF/SS; however, the Sézary clones maintain persistently aberrant immunophenotypes and seem amenable to follow-up with limited FC panels. ASC counts by FC correlated well with clinical response. Copyright

Original languageEnglish (US)
Pages (from-to)403-411
Number of pages9
JournalAmerican journal of clinical pathology
Volume137
Issue number3
DOIs
StatePublished - Mar 1 2012
Externally publishedYes

Fingerprint

Mycosis Fungoides
Flow Cytometry
Cell Count
Therapeutics
Blood Cells
Clone Cells
alemtuzumab
Electrons
Radiation
T-Lymphocytes
Skin

Keywords

  • Alemtuzumab
  • Flow cytometry
  • Immunophenotype
  • Sézary

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Immunophenotypic stability of Sézary cells by flow cytometry usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy. / Vaughan, James; Harrington, Alexandra M.; Hari, Parameswaran N.; Kroft, Steven H.; Olteanu, Horatiu.

In: American journal of clinical pathology, Vol. 137, No. 3, 01.03.2012, p. 403-411.

Research output: Contribution to journalArticle

@article{e7bece92031e47538e048aed5fd07302,
title = "Immunophenotypic stability of S{\'e}zary cells by flow cytometry usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy",
abstract = "Flow cytometry (FC) is frequently used to detect aberrant peripheral blood (PB) T cells ({"}S{\'e}zary cells{"}) in patients with mycosis fungoides (MF) and S{\'e}zary syndrome (SS). However, immunophenotypic stability of MF/SS over time is not well characterized. We analyzed 141 PB samples from 9 cases (2 SS, 7 MF). At diagnosis, there were 3 to 5 immunophenotypic aberrancies per case (median, 4), including dim or absent CD2, CD3, CD4, CD5, CD7, or CD26 and bright CD45RO. Of 9 patients, 7 had a subsequent change in immunophenotype. All patients retained multiple aberrancies at follow-up (median, 3 per analysis; range, 2-6), of which 22.0{\%} (81/369) were new. In 5 patients, a more than 99{\%} decrease in absolute S{\'e}zary cell (ASC) counts by FC after alemtuzumab therapy or total skin electron beam radiation was associated with clinical improvement. We observed minor immunophenotypic changes over time in most patients with MF/SS; however, the S{\'e}zary clones maintain persistently aberrant immunophenotypes and seem amenable to follow-up with limited FC panels. ASC counts by FC correlated well with clinical response. Copyright",
keywords = "Alemtuzumab, Flow cytometry, Immunophenotype, S{\'e}zary",
author = "James Vaughan and Harrington, {Alexandra M.} and Hari, {Parameswaran N.} and Kroft, {Steven H.} and Horatiu Olteanu",
year = "2012",
month = "3",
day = "1",
doi = "10.1309/AJCP7QHH5XASTJPL",
language = "English (US)",
volume = "137",
pages = "403--411",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - Immunophenotypic stability of Sézary cells by flow cytometry usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy

AU - Vaughan, James

AU - Harrington, Alexandra M.

AU - Hari, Parameswaran N.

AU - Kroft, Steven H.

AU - Olteanu, Horatiu

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Flow cytometry (FC) is frequently used to detect aberrant peripheral blood (PB) T cells ("Sézary cells") in patients with mycosis fungoides (MF) and Sézary syndrome (SS). However, immunophenotypic stability of MF/SS over time is not well characterized. We analyzed 141 PB samples from 9 cases (2 SS, 7 MF). At diagnosis, there were 3 to 5 immunophenotypic aberrancies per case (median, 4), including dim or absent CD2, CD3, CD4, CD5, CD7, or CD26 and bright CD45RO. Of 9 patients, 7 had a subsequent change in immunophenotype. All patients retained multiple aberrancies at follow-up (median, 3 per analysis; range, 2-6), of which 22.0% (81/369) were new. In 5 patients, a more than 99% decrease in absolute Sézary cell (ASC) counts by FC after alemtuzumab therapy or total skin electron beam radiation was associated with clinical improvement. We observed minor immunophenotypic changes over time in most patients with MF/SS; however, the Sézary clones maintain persistently aberrant immunophenotypes and seem amenable to follow-up with limited FC panels. ASC counts by FC correlated well with clinical response. Copyright

AB - Flow cytometry (FC) is frequently used to detect aberrant peripheral blood (PB) T cells ("Sézary cells") in patients with mycosis fungoides (MF) and Sézary syndrome (SS). However, immunophenotypic stability of MF/SS over time is not well characterized. We analyzed 141 PB samples from 9 cases (2 SS, 7 MF). At diagnosis, there were 3 to 5 immunophenotypic aberrancies per case (median, 4), including dim or absent CD2, CD3, CD4, CD5, CD7, or CD26 and bright CD45RO. Of 9 patients, 7 had a subsequent change in immunophenotype. All patients retained multiple aberrancies at follow-up (median, 3 per analysis; range, 2-6), of which 22.0% (81/369) were new. In 5 patients, a more than 99% decrease in absolute Sézary cell (ASC) counts by FC after alemtuzumab therapy or total skin electron beam radiation was associated with clinical improvement. We observed minor immunophenotypic changes over time in most patients with MF/SS; however, the Sézary clones maintain persistently aberrant immunophenotypes and seem amenable to follow-up with limited FC panels. ASC counts by FC correlated well with clinical response. Copyright

KW - Alemtuzumab

KW - Flow cytometry

KW - Immunophenotype

KW - Sézary

UR - http://www.scopus.com/inward/record.url?scp=84859238276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859238276&partnerID=8YFLogxK

U2 - 10.1309/AJCP7QHH5XASTJPL

DO - 10.1309/AJCP7QHH5XASTJPL

M3 - Article

C2 - 22338052

AN - SCOPUS:84859238276

VL - 137

SP - 403

EP - 411

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -